AnaptysBio (NASDAQ: ANAB) is one of 484 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare AnaptysBio to related businesses based on the strength of its analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.
Volatility & Risk
AnaptysBio has a beta of 3.27, meaning that its stock price is 227% more volatile than the S&P 500. Comparatively, AnaptysBio’s rivals have a beta of 1.08, meaning that their average stock price is 8% more volatile than the S&P 500.
This table compares AnaptysBio and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|AnaptysBio||$10.00 million||-$30.07 million||-59.27|
|AnaptysBio Competitors||$2.03 billion||$132.97 million||-3.34|
AnaptysBio’s rivals have higher revenue and earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares AnaptysBio and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and price targets for AnaptysBio and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
AnaptysBio currently has a consensus target price of $138.63, indicating a potential upside of 53.87%. As a group, “Pharmaceutical preparations” companies have a potential upside of 47.00%. Given AnaptysBio’s stronger consensus rating and higher possible upside, equities research analysts clearly believe AnaptysBio is more favorable than its rivals.
Institutional & Insider Ownership
99.3% of AnaptysBio shares are held by institutional investors. Comparatively, 47.7% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 14.9% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
AnaptysBio beats its rivals on 8 of the 13 factors compared.
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize monospecific antibody product candidates targeting TIM-3 (TSR-022), LAG-3 (TSR-033), and PD-1 (TSR-042), as well as a bispecific antibody product candidate targeting PD-1 and LAG-3; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 agonist antibody (CC-90006) that is in Phase 1 trial. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.